Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | Z27PB | — |
an adult Havrix immunization, administered to a pediatric patient, age of twelve months; an adult Havrix immunization, administered to a pediatric patient, age of twelve months; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of overdose in a 12-month-old male patient who received HAV (Havrix 1440 adult) (batch number Z27PB, expiry date 27-AUG-2026) for prophylaxis. On 22-SEP-2025, the patient received Havrix 1440 adult. On 22-SEP-2025, an unknown time after receiving Havrix 1440 adult, the patient experienced overdose (Verbatim: an adult Havrix immunization, administered to a pediatric patient, age of twelve months) and adult product administered to child (Verbatim: an adult Havrix immunization, administered to a pediatric patient, age of twelve months). The outcome of the overdose and adult product administered to child were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 22-SEP-2025 Pharmacist reported that they just wanted to contact the patient's parents to let them know about that error and they were wondering if there was anything specific that they should be looking for and if it would change the vaccinations guidelines.